The fixed-dose combination of bictegravir, emtricitabine, and tenofovir alafenamide might provide a safe and efficacious option for ongoing treatment of HIV-1 infection
Immediate and deferred switching from a boosted protease inhibitor to a dolutegravir regimen in HIV + patients is found to be highly efficacious.
Generic antiretroviral agents have had a dramatic effect on outcomes in developing nations, and their availability in developed countries is rapidly expanding as more brand-name drugs are coming off patent. But unique challenges surrounding their use remain.
Investigators assessed adherence to antiretroviral therapy, retention in care, and virologic outcomes in patients receiving once-daily single-tablet and multiple-tablet antiretroviral therapy regimens.
The rapidly developing landscape of antiretroviral therapy adherence monitoring has great potential for clinical application, but cost-effectiveness and feasibility studies are needed to define the appropriate roles for these new technologies.
Investigators sought to determine the association between antiretroviral therapy and cytomegalovirus infection in individuals with HIV, as well as the potential impact of both on neurocognitive performance.
The Copenhagen Co-morbidity in HIV Infection (COCOMO) study assessed the association between risk factors for cardiovascular disease and HIV infection.
More research is needed to better capture the interplay between prediabetes/diabetes and antiretroviral therapy in people with HIV.
Unhealthy alcohol use does not appear to have a short-term direct biological effect on CD4 cell count.
Polyomavirus JC-DNA assessment in plasma samples might complement progressive multifocal leukoencephalopathy diagnosis, especially when cerebrospinal fluid (CSF) is unavailable or polyomavirus JC-DNA is not detectable in CSF.
Benefits of urine lipoarabinomannan include its rapid point-of-care platform, low cost, and readily accessible sample type.
Mental health at the time of antiretroviral therapy initiation indicates early effect on the HIV care continuum.
Since early ART limits HIV reservoir size and preserves central memory CD4 cells, patients treated from primary HIV infection with low HIV-DNA levels might be good candidates for future HIV cure strategies.
In high-income countries, the need for second-line treatments due to the development of acquired drug resistance will increase only slightly under the new ART initiation guidelines.
In patients living with HIV receiving TDF with a ritonavir-boosted protease inhibitor, the risk of CKD may be increased.
Dr Gianella Weibel talks with Dr Li and Dr Dubé, investigators of a new study from the AIDS Clinical Trials Group, which uses an intensively monitored antiretroviral pause to identify changes in HIV reservoirs after anti-HIV medications are stopped.
Study suggests that early initiation of combination antiretroviral therapy and full viral suppression may preserve long-term brain health.
The GRADE framework recommendations provide guidance for combination treatment regimens based on 2 systemic reviews, patient considerations, fetal outcomes, and practical issues.
Abacavir-containing antiretroviral therapy does not appear to confer an increased risk for myocardial infarction or coronary artery disease.
Researchers aim to identify changes in blood lipid profiles among children with HIV after 12 months of using antiretroviral therapy.
Learn more about when stopping antiretroviral therapy (ART) may be necessary, why patients discontinue ART, predicting viral suppression, and predicting and encouraging adherence.
The combination of tenofovir disoproxil fumarate, emtricitabine, and efavirenz was associated with the lowest risk of adverse birth outcome compared to other ART treatments.
Researchers aimed to reduce incidence of hypertriglyceridemia in people with HIV undergoing cART.
Tumors, such as acute lymphocytic leukemia, cancer of the tongue, and cancer of the penis, are becoming more common in the HAART era compared with the pre-HAART era.
Point-of-care testing of HIV-exposed infants at birth yielded results comparable to the standard of care laboratory-based testing and reduced time to result and time to antiretroviral therapy initiation.
One-week amphotericin plus flucytosine was found to have comparable efficacy and safety profiles as the standard of care, 2-weeks amphotericin-based therapy, for treatment of HIV-associated cryptococcal meningitis in African patients.
A child who was diagnosed with HIV at 1 month and received early treatment has suppressed the virus without anti-HIV therapy for 8.5 years.
New WHO guidelines address the issue of how to manage pretreatment human immunodeficiency virus drug resistance (HIVDR) in countries where the prevalence of HIVDR is 10% or higher.
The combination of long-acting intramuscular cabotegravir plus rilpivirine was demonstrated to be as effective as 3-drug daily oral ART for maintaining viral suppression of HIV-1 for up to 96 weeks in the LATTE-2 phase 2b study.
Several technological advances have been developed to improve adherence to antiretroviral and preexposure prophylaxis therapy.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Tick-Caused Meat Allergy on the Rise in the United States
- Influenza-MRSA Co-Infection May Require Vancomycin Plus Second Antibiotic
- High Rates of Salmonella Contamination Identified in Kratom
- Influence of Vitamin D in HIV Infection
- Fixed-Dose Bictegravir, Emtricitabine, Tenofovir Alafenamide Is Efficacious HIV-1 Treatment Option
- Universal Purchase Programs in the United States May Not Effectively Increase Vaccination Rates
- Tick-Caused Meat Allergy on the Rise in the United States
- Delays in Lactate Testing Associated With Delayed Antibiotics, Increased Mortality in Sepsis
- Prognostic Biomarkers to Guide Antibiotic Therapy in Critically Ill Patients
- Sofosbuvir/Velpatavir Effective for HCV-Infected Liver Transplant Recipients
- PCV13 Prevents Acute Otitis Media Caused by S pneumoniae in Children
- Ceftazidime/Avibactam an Effective Option in Serious Gram-Negative Infections
- Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy
- Mosaic HIV-1 Vaccine Induces Responses in Humans and Monkeys
- FDA Announces New Drug Shortages Task Force